Repeatability of Magnetic Resonance Imaging in Patients With IDH1 Mutant Glioma on Ivosidenib

Withdrawn before enrolling · Not applicable

Conditions studied: Low Grade Glioma of Brain

In brief

The purpose of this study is to evaluate the repeatability of magnetic resonance imaging (MRI) in patients with isocitrate dehydrogenase 1 (IDH1) mutant (mIDH1) low-grade diffuse glioma \[World Health Organization (WHO) grade 2\] who are receiving off-label ivosidenib.

Key facts

Study ID

NCT06648473

Run by

Duke University

People needed

0

Starts

2026-01-01

Expected to finish

2027-12-01

Last updated by the study team

2026-01-28

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Written informed consent prior to beginning specific protocol procedures
• Scheduled for contrast-enhanced magnetic resonance imaging (MRI) as part of clinical care
• Histologically IDH1 mutant low-grade glioma (WHO grade 2) and actively receiving ivosidenib
• Active patient treatment or evaluations at the Preston Robert Tisch Brain Tumor Center at Duke
• Age ≥18 years and ≤70 years
• Karnofsky performance index ≥70%
• Primary treating physician approval

You may not qualify if…

• Inability to have MRIs

Where it is running

• Duke University Medical Center — Durham, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.